Yüklüyor......
IL10RA modulates crizotinib sensitivity in NPM1-ALK(+) anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven...
Kaydedildi:
| Yayımlandı: | Blood |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530646/ https://ncbi.nlm.nih.gov/pubmed/32573700 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003793 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|